Horizon Discovery

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

Global Genome Editing Market Research Report 2023-2035: Pharmaceutical Giants Expand Capabilities - WuXi AppTec and Ensoma Lead Acquisitions - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Genome Editing Market Report 2024: Technology Licensing Deals are Driving the Overall Partnership Activity - Global Industry Trends and Forecasts 2023-2035

Retrieved on: 
Wednesday, February 7, 2024

DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period.
  • Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies).

Reading Horizons Recommended as Supplemental Literacy Program for Grades K-3

Retrieved on: 
Wednesday, November 22, 2023

KAYSVILLE, Utah, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Reading Horizons, a leading provider of foundational literacy programs, announced today that the Utah State Board of Education approved Reading Horizons Discovery® as a recommended Supplemental Literacy Curriculum Resource.

Key Points: 
  • KAYSVILLE, Utah, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Reading Horizons , a leading provider of foundational literacy programs, announced today that the Utah State Board of Education approved Reading Horizons Discovery ® as a recommended Supplemental Literacy Curriculum Resource.
  • In 2022, Utah joined many states in realigning reading instruction to Structured Literacy grounded in the science of reading.
  • The Utah State Board of Education acknowledged Reading Horizons Discovery® as a K–3 foundational literacy program that uses systematic direct instruction to build crucial early literacy skills, supporting all students to attain reading proficiency by the end of third grade.
  • "We are in year three of implementing Reading Horizons and have found it aligns strongly with the science of reading.

Utah State Board of Education Approves Reading Horizons Discovery as a Recommended Supplemental Literacy Program for Grades K-3

Retrieved on: 
Wednesday, November 15, 2023

KAYSVILLE, Utah, Nov. 15, 2023 /PRNewswire-PRWeb/ -- Reading Horizons Recommended as Supplemental Literacy Program for Grades K–3

Key Points: 
  • Reading Horizons, a leading provider of foundational literacy programs, announced today that the Utah State Board of Education approved Reading Horizons Discovery® as a recommended Supplemental Literacy Curriculum Resource, recognizing it as a foundational literacy program that uses systematic direct instruction to build crucial early literacy skills, supporting all students to achieve reading proficiency by the end of third grade.
  • Reading Horizons , a leading provider of foundational literacy programs, announced today that the Utah State Board of Education approved Reading Horizons Discovery ® as a recommended Supplemental Literacy Curriculum Resource.
  • In 2022, Utah joined many states in realigning reading instruction to Structured Literacy grounded in the science of reading.
  • The Utah State Board of Education acknowledged Reading Horizons Discovery® as a K–3 foundational literacy program that uses systematic direct instruction to build crucial early literacy skills, supporting all students to attain reading proficiency by the end of third grade.

CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer

Retrieved on: 
Tuesday, June 6, 2023

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.

Key Points: 
  • CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.
  • Samantha joins CEO, Dr. Paul Brooks, on the executive team to guide all key commercial and strategic initiatives, drive revenue and shape CN Bio’s ongoing growth trajectory.
  • Ahead of transitioning into life sciences, Samantha qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva.
  • Dr. Samantha Macro, CFO, CN Bio, commented: “CN Bio’s OOC solutions are disruptive within the sector; capable of accurately and efficiently predicting human responses to medicines.

Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

Retrieved on: 
Tuesday, May 9, 2023

Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.

Key Points: 
  • Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.
  • Born from two words, “revolutionize” (rev) and “vita” (vit) meaning “life” in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure.
  • “We’re a translational company in the sense that our capabilities facilitate decision making between research and clinical customers,” remarked Singh.
  • The Company will trade under its new name and the stock ticker symbol "RVTY” at market open on May 16, 2023.

CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing

Retrieved on: 
Tuesday, March 14, 2023

CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing.
  • Prior to this, Deepak was with Pacific Biosciences as Vice President of EMEA Operations.
  • He also held senior-level sales and marketing positions at Affymetrix and the Genetic Analysis Unit of Applied Biosystems (formerly a PerkinElmer company).
  • Deepak Singh, VP Sales and Marketing at CN Bio, commented: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised.

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

Retrieved on: 
Monday, December 19, 2022

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect.
  • As part of the Scientific Advisory Board, CN Bio will continue to benefit from Dr David Hughes’ domain expertise and extensive technical bioengineering background.
  • In this consultative role, Dr Hughes will remain involved in the future development of CN Bio’s product and service portfolio.
  • Dr Paul Brooks, CEO at CN Bio, said: “I would like to thank David for his leadership of CN Bio through a transformational time, and I look forward to working with him as we begin to fully exploit our incredible innovation engine.

Reading Horizons Announces the Newest Edition of Reading Horizons Discovery, with Tech-Enabled Lesson Delivery that Promotes Reading Proficiency by Third Grade

Retrieved on: 
Tuesday, October 25, 2022

KAYSVILLE, Utah, Oct. 25, 2022 /PRNewswire/ -- Reading Horizons, a company committed to empowering educators to eradicate illiteracy, announced today the next generation of Reading Horizons Discovery®. The Reading Horizons multisensory method, paired with a new tech-enabled lesson delivery system, helps educators deliver effective, science-based reading instruction.

Key Points: 
  • Simplifying the science of reading, Reading Horizons Discoveryprovides a next-generation foundational reading curriculum with real-time data to differentiate instruction
    KAYSVILLE, Utah, Oct. 25, 2022 /PRNewswire/ -- Reading Horizons , a company committed to empowering educators to eradicate illiteracy, announced today the next generation of Reading Horizons Discovery.
  • The Reading Horizons multisensory method, paired with a new tech-enabled lesson delivery system, helps educators deliver effective, science-based reading instruction.
  • The new Reading Horizons Discovery provides engaging, accessible, grade-specific lessons to guide K3 students in mastering foundational reading skills.
  • "Reading Horizons Discovery will allow me to save time," saidpilot user Heather Henry, a first-grade teacher in Alabama.